announcement

19 June 2013: Anteo Diagnostics Limited (ASX: ADO) (“Anteo”), in compliance with its continuous disclosure obligations, announces that it has entered into an agreement for a Feasibility Study with a global healthcare company, to investigate and evaluate the potential of Mix&Go™. The objective of the Feasibility Study is to assess whether Mix&Go provides an advantage in the development of a new device. This will be determined by assessment of results generated by three scientists over twelve months. Depending on the outcome of the Study, and any commercial negotiations, Mix&Go may be utilised.
Anteo’s Chief Executive Officer Dr Geoff Cumming commented, “We are delighted to have entered into this agreement and continue to focus our efforts on further commercialising Mix&Go. This contract is a step forward and the ongoing feedback we receive from discussions with a number of other interested parties continues to be encouraging.”